Clacinosis occurs in damaged or devitalized tissues in the presence of normal calcium/phosphorus metabolism. It is often noted in the subcutaneous tissues in the course of connective tissues diseases – primarily systemic lupus erythematosus systemicus, sclerodermia and dermatomyositis – and may involve a relatively localized area or be widespread. The aim of the study was to discuss the classification, pathogenesis, clinical features and treatment of calcinosis in rheumatic diseases. The calcinotic accumulations may lead secondarily to muscle atrophy, join contractures and skin ulceration complicated by recurrent episodes of local inflammation and infection. Warfarin, colchicines, probenecid, bisphosphonates, diltiazem, minocycline, aluminium hydroxide, salicylate, surgical extirpation and carbon dioxide laser therapies have been used in the treatment of calcinosis. However, that kind of medication has not convincingly prevented or reduced calcinosis.